| Document |
Document Title |
|
WO/2022/151002A1 |
A glycyrrhetinic acid derivative represented by formula (I), a synthesis method therefor, a pharmaceutical composition thereof and a use thereof. The foregoing glycyrrhetic acid derivative has a structure as represented by formula (I), a...
|
|
WO/2022/155614A1 |
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...
|
|
WO/2022/124840A1 |
The present invention provides a sea cucumber genital gland extract, preferably, a novel saponin compound separated from an ovary extract, and the novel use of a sea cucumber genital gland extract or a compound separated from a sea cucum...
|
|
WO/2022/056439A1 |
The present disclosure relates to synthetic triterpenoids, methods for preparing such synthetic triterpenoids, and methods of using such synthetic triterpenoids to treat and/or prevent diseases or disorders such as cancers, particularly ...
|
|
WO/2022/041126A1 |
Provided are a glycyrrhizic acid derivative represented by formula (I) and a pharmaceutical composition thereof. The symbols in formula (I) are as defined in the description. Same can inhibit flaviviruses, such as dengue virus and Zika v...
|
|
WO/2022/031359A1 |
Substantially pure saponin extracts and orthogonal chromatographic methods for purification of saponin extracts are disclosed. The purified saponin extracts may include QS-21 and can have a purity of greater than 97%. The orthogonal chro...
|
|
WO/2022/031130A1 |
The present invention relates to an ester derivative precursor drug of inotodiol and a use thereof. The precursor drug has an increased solubility in an inorganic solvent and an organic solvent and an improved stability and as such, can ...
|
|
WO/2022/007765A1 |
The present invention provides a pentacyclic triterpenoid glycoside compound, and a preparation method therefor and a use thereof. Specifically, the present invention provides a compound as shown in formula I. The definition of each grou...
|
|
WO/2022/006145A1 |
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/240349A1 |
The present invention relates to a method for the production of high amounts of triterpenic acids by an in vitro culture of calluses deriving from the pulp of apples of Red Sentinel (RS) variety, and to in vitro cultures of calluses deri...
|
|
WO/2021/179884A1 |
The present invention belongs to the field of the pharmaceutical chemistry, and particularly relates to an oleanolic acid derivative having a conjugated diene structure C ring, and a preparation method therefor and the use thereof. In pa...
|
|
WO/2021/161206A1 |
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n, and ring (II) are as defined in formula (I). The invention also relates to novel trit...
|
|
WO/2021/139395A1 |
Disclosed is a high-efficiency low-toxicity anti-cancer compound synthesized by autocatalysis in cells and living bodies. The anti-cancer compound is prepared by means of chemical synthesis of a metal complex precursor and an organic act...
|
|
WO/2021/134408A1 |
The present invention relates to preparation, impurity removal and purification methods for glycyrrhizic acid monovalent salt. The preparation method for glycyrrhizic acid monovalent salt comprises mixing a glycyrrhizinate mixture and a ...
|
|
WO/2021/134407A1 |
A method for extracting a crude product of glycyrrhizic acid and glycyrrhizic flavone from licorice and purifying to obtain glycyrrhizinate. In the method, a medicinal material of licorice and an organic solvent are mixed at a certain ra...
|
|
WO/2021/122998A1 |
The present invention relates to novel saponins of formula (I), comprising acetyl residues on two of their sugar residues. These saponins are able to enhance the transfection efficiency to a high extent and show much less cytotoxic side ...
|
|
WO/2021/127480A1 |
In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions pro...
|
|
WO/2021/109836A1 |
Disclosed in the present invention are a tea saponin compound, a preparation method therefor, and an application thereof. The structural general formula of the tea saponin compound is as represented by formula (I). It is proved in the pr...
|
|
WO/2021/104391A1 |
The present invention relates to the field of pharmaceutical chemistry and the field of pharmacotherapeutics, and in particular, to a 2-cyano-3,12-dioxooleanane-1,9(11)-diene-17-cinnamamide derivative and a preparation method therefor; a...
|
|
WO/2021/085291A1 |
The purpose of the present invention is to provide: a composition for TGR5 activation, said composition comprising, as an active ingredient, a substance that has an effect of activating TGR5 and shows a high selectivity for TGR5; and a m...
|
|
WO/2021/078150A1 |
A pentacyclic triterpene TGR5 receptor agonist and a preparation method therefor and uses thereof. The structure of the pentacyclic triterpene TGR5 receptor agonist is as shown in formula I, and the definition of each substituent group i...
|
|
WO/2021/047672A1 |
Disclosed herein are triterpenoid compounds, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also disclosed herein are methods of their use for treat.
|
|
WO/2021/016191A1 |
Disclosed herein are compounds of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidan...
|
|
WO/2020/259205A1 |
Disclosed are derivatives of novel pentacyclic triterpenoid AMPK agonists, oleanolic acid and δ-oleanolic acid, and medicinal use thereof, specifically, a compound represented by formula I or formula II, and a pharmaceutically acceptabl...
|
|
WO/2020/264509A1 |
Provided herein is a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VII, VIII, IX, or XI: or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VI...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/253814A1 |
The present application relates to a class of tripterine derivatives represented by formula I, a preparation method therefor and the use thereof. The tripterine derivatives have a significant Prdx1 inhibitory activity, can be used for pr...
|
|
WO/2020/221113A1 |
Provided by the present invention is a preparation method for momordin Ib, comprising: first, mixing a plant containing a triterpene saponin derivative having the structural unit shown in formula (I) or a plant extract containing a trite...
|
|
WO/2020/198883A1 |
Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.
|
|
WO/2020/180661A1 |
This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosur...
|
|
WO/2020/165742A1 |
The present invention relates to novel triterpenone derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The invention also relates to novel triterpenone deri...
|
|
WO/2020/165741A1 |
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivativ...
|
|
WO/2020/163642A1 |
The present invention provides a compound of formula (I) or a salt thereof: (F ormula (I)) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD...
|
|
WO/2020/161221A1 |
The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composi...
|
|
WO/2020/143640A1 |
The present invention relates to a steroid compound, and a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokin...
|
|
WO/2020/121161A1 |
The present invention relates to the mesylate (CH3SO2) salt of the following compound (I).
|
|
WO/2020/096486A1 |
The invention relates to the field of medicine and to the chemical and pharmaceutical industry, and concerns agents for treating cancer. 3-O-sulfamate-16,16-dimethyl-D-homoequilenin is proposed as an anti-cancer agent in monotherapy and ...
|
|
WO/2020/068689A1 |
Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.
|
|
WO/2020/006510A1 |
The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicament...
|
|
WO/2019/207460A1 |
The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R1 is Formula (AA) or Formula (BB) where the squiggly line indicates the point of attachment to the rest of the mole...
|
|
WO/2019/186342A1 |
The present invention discloses certain ionic liquid salts of 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R) -2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl-5a,5b,8,8,1 1 a-pentamethyl-2- oxo-3,3a,4,5,5a,...
|
|
WO/2019/191637A1 |
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
|
|
WO/2019/126761A1 |
Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herei...
|
|
WO/2019/079160A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
|
WO/2019/060051A1 |
The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used t...
|
|
WO/2019/052560A1 |
Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
|
|
WO/2019/054379A1 |
The present invention pertains to a compound represented by formula (I) or a salt thereof. [In formula (I), ring C is a hydrocarbon ring, etc.; the hydrocarbon ring, etc., has a substituent group selected from the group consisting of hyd...
|
|
WO/2019/018940A1 |
Natural sweetener compositions are disclosed, which generally include steviol glycosides extracted from a Stevia rebaudiana plant and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally f...
|
